Emerald raises £2.9m to embed preventive health in fintech and benefits
Emerald, the UK-based preventive healthcare platform, has closed a £1.4 million funding round combining a second Innovate UK grant of £700,000 with an equivalent tranche of venture capital from new backers Sequel and Highgoal alongside its existing investors. The round lifts Emerald's total funding since its 2024 launch to £2.9 million and comes as the company reports that its member base has grown tenfold in 2026, with more than 100,000 laboratory tests processed to date.
The platform integrates in-clinic laboratory screening, wearable data, health history and GP-led care into a single regulated environment. Emerald is registered with the Care Quality Commission and holds UKCA Class I medical device authorisation from the MHRA, meaning it can offer diagnostic screening, prescriptions and formal NHS referrals. The company says two thirds of members who have undergone repeat screening have shown improvements in cholesterol, roughly a third have seen blood-sugar levels fall, and close to half have recorded reduced inflammation markers.
From clinic to distribution channel
The more strategically significant detail for cross-sector observers is not the clinical data but the distribution architecture Emerald is building around it. Over the past year the company has signed revenue-generating partnerships with Pluxee, Epassi and Yonder, embedding its screening and GP-support service inside employee-benefits and fintech-rewards platforms. The model effectively turns health data into an employee-benefit product that sits alongside pension contributions and salary-sacrifice schemes rather than beside a GP surgery.
That positioning matters because it routes preventive healthcare through the corporate spending decisions of HR and finance directors rather than through NHS referral pathways or consumer-health app stores. For fintech platforms already managing payroll, savings and insurance products, the addition of a regulated health-screening layer deepens switching costs and broadens the data relationship with the end user. Emerald's stated ambition of one million members in three years is, on this reading, less a healthcare target than a distribution-partnership target.
CEO and co-founder Alexander Badalyan frames the commercial logic in terms of national health policy: "Achieving this ambition is a cornerstone of the current Government's health agenda, but the NHS cannot deliver this shift alone. Government efforts must be matched with innovative solutions that are able to have widespread reach. Emerald has unlocked access to millions of potential users through its partnerships."
Innovate UK and the AI health data layer
The Innovate UK grant is specifically allocated to expanding Emerald's AI applications and underlying technology. Chris Sawyer, Innovate UK's Innovation Lead for Digital Health, described the investment as supporting "AI-enabled technology designed to help clinicians deliver more personalised, proactive care." The grant signals that the UK government's health-innovation agenda is increasingly converging with the country's broader AI industrial strategy, channelling public R&D funding into platforms that can demonstrate population-scale data collection alongside regulated clinical delivery.
That convergence has wider capital implications. Employer-benefits platforms and consumer fintech players are under pressure to differentiate beyond cashback and savings rates. Regulated health data, particularly longitudinal screening data that accumulates value over time, represents a genuinely sticky product layer. Investors active across insurtech, HR-tech and digital health are already examining how preventive-care infrastructure plugs into existing fintech distribution rails, a dynamic that Emerald's partnership model makes explicit. At £2.9 million in total funding, Emerald remains early-stage, but the architecture it is assembling, regulated clinical services delivered through fintech and benefits distribution channels, prefigures a structural shift in how preventive healthcare is financed and accessed in the UK and potentially across comparable universal-healthcare systems in Europe.
The next inflection point will be whether the partnership pipeline can sustain the member-growth trajectory without a significantly larger capital raise, and whether the AI layer can demonstrate enough clinical differentiation to justify embedding in regulated financial-services products.